Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.47 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 3/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2906912 | 0.90 | KMT2A (0.50) | KMT2ASMN1; SMN2KDM4EMETTL3CHRNB2 | |
| SCHEMBL2906910 | 0.90 | KMT2A (0.50) | KMT2ASMN1; SMN2KDM4EMETTL3CHRNB2 | |
| SCHEMBL2902476 | 0.83 | KDM4E (0.46) | KMT2ASMN1; SMN2KDM4ECHRNB2CHRNA7 | |
| SCHEMBL2901762 | 0.83 | KDM4E (0.46) | KMT2ASMN1; SMN2KDM4ECHRNB2CHRNA7 | |
| SCHEMBL2901764 | 0.83 | KDM4E (0.46) | KMT2ASMN1; SMN2KDM4ECHRNB2CHRNA7 | |
| SCHEMBL10154196 | 0.81 | KMT2A (0.49) | KMT2ASMN1; SMN2KDM4ETRPV1CHRNB2 | |
| SCHEMBL10154259 | 0.79 | MGAM (0.54) | KMT2ASMN1; SMN2TRPV1METTL3CHRNB2 | |
| SCHEMBL13096310 | 0.75 | KDM4E (0.58) | KMT2ASMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL4238969 | 0.74 | FAAH (0.48) | KMT2AMETTL3CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL2905047 | 0.73 | KDM4E (0.48) | KMT2AKDM4ECHRNB2CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110683-B2 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-07 | — | — | US | disclosed |
| US-20110092528-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | DE CORTE BART | 2011-04-21 | — | — | US | disclosed |
| WO-2009058314-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092528-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | ITGB3, ITGAV, ITGA2B | KMT2A 3633/4885SMN1; SMN2 1988/4885KDM4E 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.